Skip to Content

GlaxoSmithKline PLC GSK

Rating as of

Morningstar’s Analysis

Valuation
Currency in GBX
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Likely Democrat Senate Control Ups Potential for New Drug Policies, but Major Changes Look Unlikely

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

With the Democrats being very close to winning the remaining two Senate seats in the Georgia runoffs, we expect the Biden administration will seek to implement further healthcare reforms. However, with such a slim possible majority in the Senate, we expect significant compromises that will likely lead to watered-down drug policy changes. We continue to view the biopharma group as undervalued with strong underlying fundamentals, but we expect lingering concern about drug policy changes to weigh on the industry's valuations. 

Read Full Analysis

Company Profile

Business Description

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.

Contact
980 Great West Road
Brentford, Middlesex, TW8 9GS, United Kingdom
T +44 2080475000
Sector Healthcare
Industry Drug Manufacturers - General
Most Recent Earnings Sep 30, 2020
Fiscal Year End Dec 31, 2020
Stock Type
Employees 99,437

Related